Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases

Avidity Biosciences, Inc. (NASDAQ: RNA ) is rapidly growing into a potential leader in RNA-based genetic therapies, leveraging its Antibody Oligonucleotide Conjugates [AOCs] technology. Since my previous May 2024 article, the stock has appreciated by about 20.3%. This move likely reflects toMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, A ...